Literature DB >> 10828724

IgG immune complex binding to and activation of liver cells. An in vitro study with IgG immune complexes, Kupffer cells, sinusoidal endothelial cells and hepatocytes.

A G Johansson1, T Sundqvist, T Skogh.   

Abstract

BACKGROUND/AIMS: The aim was to study IgG immune complex (IC) binding to isolated hepatocytes, Kupffer cells (KCs) and sinusoidal endothelial cells (SECs). Further, we wished to analyze the capacity of IgG ICs to induce release of reactive oxygen metabolites by the IC-binding liver cells.
METHODS: ICs were formed between (125)I-tyramine-cellobiose-labelled dinitrophenyl-conjugated human serum albumin ((125)I-TC-DNP(10)HSA) and polyclonal rabbit IgG antibodies. Binding of ICs to different rat liver cells in suspension was studied at 4 degrees C. Production of reactive oxygen metabolites was measured by luminol-enhanced chemiluminescence at 37 degrees C.
RESULTS: IgG mediated binding of (125)I-TC-DNP(10)HSA to both KCs and SECs, but not to hepatocytes. The binding showed saturation kinetics and was blocked by an excess of unlabelled IgG-ICs. IgG-ICs activated KCs, but not SECs, to a chemiluminescence response.
CONCLUSIONS: Both KCs and SECs bind IgG-ICs in vitro, probably via Fc receptor interaction. IgG-ICs activate KCs to produce reactive oxygen metabolites. The binding of IgG-ICs to isolated hepatocytes is small. Copyright 2000 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10828724     DOI: 10.1159/000024347

Source DB:  PubMed          Journal:  Int Arch Allergy Immunol        ISSN: 1018-2438            Impact factor:   2.749


  4 in total

1.  Infliximab exerts no direct hepatotoxic effect on HepG2 cells in vitro.

Authors:  Hilbert S de Vries; Tineke de Heij; Henie M J Roelofs; Rene H M te Morsche; Wilbert H M Peters; Dirk J de Jong
Journal:  Dig Dis Sci       Date:  2012-04-26       Impact factor: 3.199

Review 2.  Intravascular immunity: the host-pathogen encounter in blood vessels.

Authors:  Michael J Hickey; Paul Kubes
Journal:  Nat Rev Immunol       Date:  2009-05       Impact factor: 53.106

Review 3.  The Contribution of Liver Sinusoidal Endothelial Cells to Clearance of Therapeutic Antibody.

Authors:  Bethany H James; Pantelitsa Papakyriacou; Matthew J Gardener; Louise Gliddon; Christopher J Weston; Patricia F Lalor
Journal:  Front Physiol       Date:  2022-01-14       Impact factor: 4.566

4.  Cholestatic liver disease after rituximab and adalimumab and the possible role of cross-reacting antibodies to Fab 2 fragments.

Authors:  Joerg Latus; Reinhild Klein; Ina Koetter; Matthias Schwab; Peter Fritz; Martin Kimmel; M Dominik Alscher; Niko Braun
Journal:  PLoS One       Date:  2013-11-11       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.